drugset / Trial / NCT05055908
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2025-07-01
- Completion
- 2027-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |